Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 86

TitleReference numberPublishedLast updated
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTG696
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Lung cancer: diagnosis and managementNG122
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898

Results per page

  1. 10
  2. 25
  3. 50
  4. All